

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 64

January 24, 2022

ISSUE No.  
**1642**

### IN THIS ISSUE

Molnupiravir for Treatment of COVID-19.....p 10

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Volume 64 (Issue 1642)

January 24, 2022

Take CME Exams

### ▶ Molnupiravir for Treatment of COVID-19

The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of mild to moderate COVID-19 in outpatients  $\geq 18$  years old who are at high risk of progressing to severe disease, including hospitalization or death (see Table 1), and for whom alternative treatment options are not available or clinically appropriate.<sup>1</sup> *Paxlovid* (Pfizer), nirmatrelvir copackaged with ritonavir, was granted an EUA on December 22, 2021.<sup>2</sup> The IV antiviral drug remdesivir (*Veklury*) was approved by the FDA in 2020 for treatment of COVID-19 in hospitalized patients.<sup>3</sup>

**MECHANISM OF ACTION** — Molnupiravir is a small-molecule prodrug of the synthetic nucleoside derivative N-hydroxycytidine (NHC). It targets viral RNA polymerase, inducing mutagenesis and inhibiting SARS-CoV-2 replication.

**CLINICAL STUDIES** — Issuance of the EUA for molnupiravir was based on the results of a randomized, double-blind, placebo-controlled trial (MOVE-OUT) in 1433 nonhospitalized, unvaccinated adults with mild to moderate COVID-19. Eligible participants had laboratory-confirmed SARS-CoV-2 infection (most commonly with the Delta variant) with symptom onset within 5 days of randomization and at least one risk factor associated with progression to severe disease. Molnupiravir 800 mg twice daily for 5 days decreased all-cause hospitalization or death through day 29 by 30% compared to placebo (6.8% vs 9.7%). There were 9 deaths in the placebo group versus 1 death in the molnupiravir group.<sup>4,5</sup>

In a trial (MOVE-IN) in hospitalized adults with COVID-19, there was no difference between molnupiravir and placebo in the time to sustained recovery.<sup>6</sup>

**ADVERSE EFFECTS** — Rates of adverse effects such as diarrhea, nausea, and dizziness were similar with molnupiravir and placebo.

Table 1. Some High-Risk Conditions for COVID-19 Progression<sup>1</sup>

- ▶ Age  $\geq 65$  years
- ▶ BMI  $\geq 25$  kg/m<sup>2</sup> (or, in patients 12-17 years old, BMI  $\geq 85$ th percentile for age and gender<sup>2</sup>)
- ▶ Pregnancy or recent pregnancy
- ▶ Chronic kidney disease
- ▶ Chronic liver disease
- ▶ Current or former smoker or substance use disorder
- ▶ Malignancy
- ▶ Tuberculosis
- ▶ Down syndrome
- ▶ Diabetes
- ▶ Cardiovascular disease
- ▶ Hypertension
- ▶ COPD, moderate to severe asthma, or other chronic respiratory disease
- ▶ Immunosuppressive disease or currently receiving immunosuppressive treatment
- ▶ Sickle cell disease or thalassemia
- ▶ Congenital or acquired heart disease
- ▶ Dementia, neurodevelopmental disorders (e.g., cerebral palsy) or other conditions that confer medical complexity
- ▶ A medical-related technological dependence (e.g., tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])

BMI = body mass index; COPD = chronic obstructive pulmonary disease  
1. Adult and pediatric patients ( $\geq 12$  years old and weighing  $\geq 40$  kg) with  $\geq 1$  of the criteria listed are considered at high risk for progressing to severe COVID-19 or hospitalization. Available at: <https://bit.ly/3JILJD2>. Accessed January 6, 2022.  
2. Based on CDC growth charts. Available at: <https://bit.ly/36U0twf>. Accessed January 6, 2022.

Potential risks of molnupiravir include embryofetal toxicity, impaired bone and cartilage growth (the drug is not recommended for use in patients  $< 18$  years old), and mutagenicity. Viral mutations theoretically could promote development of new SARS-CoV-2 variants.

**DRUG INTERACTIONS** — No clinically significant drug interactions with molnupiravir have been identified. It is not metabolized by CYP450 isozymes and is only minimally excreted by the kidneys.

**PREGNANCY AND LACTATION** — Molnupiravir has been associated with teratogenicity and embryotoxicity in animal studies. It should not be used during pregnancy. Women of childbearing potential should use effective contraception during treatment with molnupiravir and for 4 days after the last dose. Male patients with female partners of childbearing

potential should use effective contraception during treatment and for at least 3 months after the last dose.

No data are available on the presence of molnupiravir or its metabolites in human breast milk or its effects on the breastfed infant or milk production. The drug was detected in the plasma of pups of lactating rats treated with molnupiravir. Women should not breastfeed during treatment with molnupiravir and for 4 days after the last dose.

**VARIANTS** – The nucleoside analog metabolite of molnupiravir retains activity against the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants in culture assays. According to the manufacturer, molnupiravir, based on its mechanism of action, should also be effective against the Omicron (B.1.1.529) variant.

**DOSAGE AND ADMINISTRATION** – Molnupiravir is supplied in 200-mg capsules. The recommended dosage is 800 mg every 12 hours for 5 days. Treatment should be started within 5 days of symptom onset. If a dose is missed by more than 10 hours, it should be skipped and the next dose should be taken at the regularly scheduled time. Unlike *Paxlovid*, molnupiravir can be used in patients with severe renal or hepatic (Child-Pugh C) impairment.

**CONCLUSION** – The FDA has issued an Emergency Use Authorization for the oral antiviral drug molnupiravir (Merck) for outpatient treatment of mild to moderate COVID-19 in certain high-risk adults. The drug should be started as soon as possible after diagnosis and within 5 days of symptom onset. In one trial, molnupiravir decreased all-cause hospitalization or death by 30% in outpatients with mild to moderate COVID-19. The drug should be reserved for nonpregnant, adult outpatients for whom alternative treatment options are not available or clinically appropriate. If *Paxlovid* is available, it should generally be tried first. ■

1. FDA. Fact sheet for health care providers: Emergency Use Authorization for molnupiravir. December 23, 2021. Available at: <https://bit.ly/3FSVSe2>. Accessed January 6, 2022.
2. FDA. Fact sheet for health care providers: Emergency Use Authorization for Paxlovid. December 22, 2021. Available at: <https://bit.ly/3sTNGqh>. Accessed January 6, 2022.
3. Remdesivir (Veklury) for Covid-19. *Med Lett Drugs Ther* 2020; 62:186.
4. AJ Bernal et al. Molnupiravir for oral treatment of Covid-19 in non-hospitalized patients. *N Engl J Med* 2021 December 16 (epub).
5. FDA. Addendum to FDA briefing document. Antimicrobial Drugs Advisory Committee Meeting. November 30, 2021. Available at: <https://bit.ly/3FUuOOv>. Accessed January 6, 2022.
6. JR Arribas et al. Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19. *N Engl J Med Evidence* 2021 December 16 (epub). Available at: <https://bit.ly/3t4Dg7k>. Accessed January 6, 2022.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School  
**VICE PRESIDENT AND EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli  
**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

#### Address:

The Medical Letter, Inc.  
 145 Huguenot St. Ste. 312  
 New Rochelle, NY 10801-7537  
[www.medicalletter.org](http://www.medicalletter.org)

#### Customer Service:

Call: 800-211-2769 or 914-235-0500  
 Fax: 914-632-1733  
 E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

#### Permissions:

To reproduce any portion of this issue, please e-mail your request to: [permissions@medicalletter.org](mailto:permissions@medicalletter.org)

#### Subscriptions (US):

1 year - \$159; 2 years - \$298;  
 3 years - \$398. \$65 per year  
 for students, interns, residents,  
 and fellows in the US and Canada.  
 Reprints - \$45 per issue or article

#### Site License Inquiries:

E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
 Call: 800-211-2769  
 Special rates available for bulk  
 subscriptions.